Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ACRV
Stock Latest News
Company Announcements
Acrivon Therapeutics Holds Annual Stockholders Meeting
1M ago
8K
ACRV
Premium
Ratings
Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy Rating
2M ago
ACRV
Premium
The Fly
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch
2M ago
ACRV
Premium
Ratings
Acrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating
2M ago
ACRV
Premium
Company Announcements
Acrivon Therapeutics Reports Q1 2025 Progress and Financials
2M ago
ACRV
Premium
The Fly
Acrivon Therapeutics price target lowered to $9 from $10 at Oppenheimer
2M ago
ACRV
Premium
Ratings
Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer
2M ago
ACRV
Premium
The Fly
Acrivon Therapeutics reports Q1 EPS (51c), consensus (65c)
2M ago
ACRV
Premium
The Fly
Acrivon Therapeutics sees cash, equivalents funding expenses into 2Q27
2M ago
ACRV
Premium
The Fly
Acrivon Therapeutics assumed with an Overweight at Piper Sandler
3M ago
ACRV
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
3M ago
ACRV
AZTR
Premium
The Fly
Acrivon Therapeutics to present data from analyses of ACR-2316 at AACR
3M ago
ACRV
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
3M ago
NBY
PTN
Premium
Company Announcements
Acrivon Therapeutics Reports Progress in Cancer Drug Development
4M ago
ACRV
Premium
Company Announcements
Acrivon Therapeutics Appoints New Chief Medical Officer
4M ago
8K
ACRV
Premium
The Fly
Acrivon appoints Mansoor Raza Mirza as Chief Medical Officer
4M ago
ACRV
Premium
Ratings
Buy Rating Reaffirmed for Acrivon Therapeutics Amid Promising Endometrial Cancer Data and Strong Financial Position
4M ago
ACRV
Premium
The Fly
Acrivon Therapeutics price target lowered to $7 from $22 at JonesResearch
4M ago
ACRV
Premium
The Fly
Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer
4M ago
ACRV
Premium
The Fly
Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c)
4M ago
ACRV
Premium
Company Announcements
Acrivon Therapeutics Reports 2024 Financial Results and Progress
4M ago
8K
ACRV
Premium
Ratings
Promising Phase 2 Results for ACR-368 in Endometrial Cancer Justify Buy Rating
4M ago
ACRV
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
